Investor Alert

New York Markets Close in:

The Conversation Archives | Email alerts

Dec. 9, 2020, 3:12 p.m. EST

Children probably won’t get a COVID-19 vaccine before the next school year — here’s why

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

By Wesley Kufel

The first U.S. COVID-19 vaccines are expected in clinics in mid-December, and  states are drawing up plans  for  who should get vaccinated first .

But one important group is absent: children.

While two vaccines are  expected to be cleared soon  for adult use in the U.S., testing is only now getting started with children — and only with adolescents. There are still a lot of unknowns.

As an  infectious disease pharmacist and professor  who helps manage patients hospitalized with COVID-19, I frequently hear questions about vaccines. Here’s what we know and don’t know in response to some common questions about vaccinating kids for COVID-19.

Right now, it appears  unlikely  that a vaccine will be ready for children before the start of the next school year in August.

Adult trials of the two leading vaccines have had  promising results . A  Food and Drug Administration briefing paper  released on Dec. 8 indicated the vaccine made by Pfizer appeared to meet U.S. standards for  emergency use authorization  for adults, suggesting it was on the cusp of approval. The British government has already approved the vaccine and  started vaccinating adults in the U.K.

But clinical trials involving children are only just getting started.

Pfizer, working with Germany’s BioNTech, expanded its COVID-19 vaccine testing  to children ages 12 and older  only in October. The other leading vaccine maker, Moderna,  announced on Dec. 2  that it planned to begin COVID-19 vaccine trials in children ages 12-17 soon.

The vaccine’s efficacy and safety will have to be evaluated for each age group, and testing hasn’t started for infants, toddlers or kids in the U.S.

Clinical trials are designed to ensure that the vaccine is safe and effective. Typically, it takes  10 to 15 years  from the start of development until the vaccine is licensed, but the COVID-19 vaccines are being  developed   faster  in response to the pandemic.

It does not appear that the schedule of COVID-19 vaccine doses will be different for children, but that could change as testing goes on.

Pfizer’s vaccine is being tested in adolescents with a two-dose series, three weeks apart, just like in adults. Moderna also plans to use its adult schedule — two doses four weeks apart — in an upcoming  trial with 3,000 adolescents .

The second dose serves as a “booster shot,” since the first dose alone doesn’t provide optimal immunity. This is  consistent with several other vaccines , including hepatitis B, measles, mumps and rubella.

Right now, only those two doses are planned, but that could change. It’s unclear how long the immune response from these COVID-19 vaccines will last or if more doses will be necessary in the future. The flu vaccine, for example, requires a new dose every year because the virus changes. Recent promising  data from Moderna indicate immunity is sustained  for at least three months after receiving the COVID-19 vaccine.

So far, no serious safety concerns have been identified with either the Pfizer or Moderna vaccines, but the trials are still in the early stages for children. Several  other vaccines are also under development  around the world, and a few drugmakers have  started trials with younger children  in other countries.

Another concern people raise is about  temporary side effects .

Children tend to have stronger immune systems than adults, and they may have stronger temporary reactions to the vaccine. That could mean more pain and swelling at the injection site for a few days and possibly a fever.

1 2
This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.